[Effects of therapy with various groups of antianginal agents on life quality of the elderly with coronary heart disease and comorbid depression].
The purpose of the work was to study effects of antianginal agents of various groups on the psychoemotional status and life quality (LQ) of elderly patients with coronary heart disease (CHD) and concomitant depression. The subjects of the study were 70 patients (35 men and 35 women) with stable angina and depression. The subjects were divided into 3 groups. The 20 patients of group I were administered nitrates, the 32 patients of group II--beta-adrenoblockers, and the 18 patients of group III--a Ca antagonist. The control group consisted of 27 patients without anxious depression. The treatment led to significant reduction of weakly attack frequency and weakly sublingual nitroglycerine consumption in all the three groups. Significant reduction of average depression score and personal anxiety was noted in group III; decrease of situational anxiety level was observed in group I. There was no change of the psychoemotional status in group II. Examination of patients with depression showed that their LQ, according to Nottingham Health Profile questionnaire, was significantly lower than that of patients without depression. In spite of more pronounced antianginal effect of beta-adrenoblockers, LQ in this group did not differ significantly from that in other groups. There was significant improvement of LQ in group I and III. The latter demonstrated even more prominent changes, consisting in positive dynamics of the emotional status and improvement of sleep. Despite antianginal agents, LQ of patients with depression remained significantly worse than that of patients who did not have depression prior to the therapy. Thus, correction of concomitant depression will lead not only to improvement of LQ, but perhaps, also to improvement of the prognosis of patients with CHD.
Shangina
O A
OA
Kostin
V I
VI
Koturga
L I
LI
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000367:Age Factors; D000368:Aged; D001262:Atenolol / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003863:Depression / Q000150:complications* / Q000523:psychology; D018450:Disease Progression; D005260:Female; D006801:Humans; D017275:Isradipine / Q000627:therapeutic use; D008297:Male; D017202:Myocardial Ischemia / Q000150:complications / Q000188:drug therapy / Q000523:psychology*; D005996:Nitroglycerin / Q000627:therapeutic use; D011788:Quality of Life; D012307:Risk Factors; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D014665:Vasodilator Agents; D001262:Atenolol; D005996:Nitroglycerin; D017275:Isradipine